Cancer diagnostic company Signal Genetics files and sets terms for $25 million IPO

By
A A A

Signal Genetics, which develops and sells cancer diagnostics, announced terms for its IPO on Wednesday. The New York, NY-based company plans to raise $25 million by offering 2.3 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Signal Genetics would command a market value of $53 million.

Signal Genetics, which was founded in 2010 and booked $4 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol SGNL. Signal Genetics initially filed confidentially on November 12, 2013. Aegis Capital is the sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

110,219,031
  • $6.79 ▲ 14.31%
104,982,008
  • $11.83 ▲ 12.35%
95,065,355
  • $3.40 ▲ 0.59%
79,694,763
  • $36.59 ▲ 2.64%
49,037,292
  • $39.90 ▲ 5.81%
47,069,528
  • $15.34 ▼ 1.03%
43,387,835
  • $6.56 ▼ 1.94%
42,066,487
  • $98.38 ▼ 0.65%
As of 7/29/2014, 04:04 PM